Aquila Bioscience Ltd

Aquila Bioscience Ltd

Aquila Bioscience Ltd

Business Description:

Aquila Bioscience Limited (ABL) is a biomedical design and development SME which has developed an innovative Pathogen Capture Technology (PCT) that uses natural biomolecules to safely capture and neutralise pathogens. ABL’s pathogen capture technology applies to all infectious microbes, dormant spores and many biological toxins making it a versatile disease control agent for security, healthcare, and consumer markets. Aquila’s technology is also effective to manage healthy skin.

Currently, all disinfection and decontamination products are based on biocides and other chemicals that have harmful effect on human skin and health, moreover, these chemicals cause damage to the environment. ABL’s technology is inspired by nature’s mechanisms of protecting us in a safe and effective manner without causing any damage to our health and to the environment.

Products and Services:

Aquila Bioscience (ABL) is based in Ireland and funded by the European Defence Agency and the European Innovation Council. ABL is operating to ISO13485 standards with its initial product, the ABD (Anti-Bioagent Decontamination) device which comes as a single pack sterile decontamination wipe. ABD is US FDA registered Class I Medical Device and has been shown to be 99.99% effective against SARS-CoV-2 and a number of other viral, bacterial and fungal pathogens.

Inspired by nature, ABL’s technology is non-toxic, non-flammable, will not irritate the skin or digestive system if consumed, remains effective in water and therefore has applications in a broad range of markets such as health, security, industry, animal, and food.

ABL has also developed a spray version of its technology, ProShield Spray which is capable of increasing the efficiency of fabric material in blocking pathogen from ca 40% to 99%, therefore, reducing the transmission of pathogens significantly without any harmful effect on people and the environment.

Value Proposition:

As the global health crisis and environmental crisis are converging and resulting in diseases such as COVID pandemic, there is an urgent need to develop healthcare solutions that are not only effective but are also environmentally friendly and do not add to the damage caused by many of the current products.

Aquila Bioscience has developed a revolutionary technology that can capture and remove all pathogens including viruses, bacteria, fungi and their mutants in a safe and effective manner. The technology can be applied in many different fields and products ranging from bio-defence and healthcare to personal health management. ABL’s current products are pioneering biocide-free, non-flammable products to capture and remove pathogens effectively. The technology consists of safe molecules that do not irritate skin and can be safely used on sensitive skin surfaces such as face, around the eyes, nose and mouth and mucosal surfaces to disinfect these ports of entry from pathogens.

Standards and Certificates:

ABL is operating to ISO13485 standards and is working with external partners for scaled-up manufacturing

Sector(s) Served:

Diagnostics; Healthcare; Life Sciences; Med Devices; Medical; Medtech

Key Clients:

Defence, healthcare, government agencies, general consumers

Key Partners:

SMEs and MNCs

Geographical Market(s) Served:

Global

Contact Details:

Tel: +353 87 288 2190

Email: info@aquilabioscience.com

Website: www.aquilabioscience.com